Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 01)
Citalopram Tablet
Product Images NDC 50090-5172
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Citalopram (NDC 50090-5172). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 02)
Table 1 shows the drug-placebo difference in the number of cases of suicidality per 1000 patients treated, broken down by age range. For patients under 18, there were 14 additional cases of suicidality compared to placebo. For patients aged 18-24, there were 1624 additional cases, and for patients aged 25-64, there were 564 fewer cases compared to placebo. For patients over 64, there were 265 fewer cases compared to placebo.*
Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 03)
The text presents a table showing the percentage of patients experiencing adverse events during clinical trials of citalopram compared to a placebo. The adverse events are classified by body system, including autonomic nervous system disorders, central and peripheral nervous system disorders, gastrointestinal disorders, general, musculoskeletal system disorders, psychiatric disorders, respiratory system disorders, and urogenital. Adverse events reported by at least 2% of patients on citalopram are included in the table. The denominator used for calculation differs for certain adverse events.*
Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 04)
This is a table that presents the percentage of patients who discontinued treatment due to adverse events in short-term, placebo-controlled depression trials. The table shows the number of patients in each group (citalopram and placebo) and the adverse events related to different body systems such as general, gastrointestinal, central and peripheral nervous system, and psychiatric disorders. For example, asthenia, dry mouth, and dizziness were reported in the citalopram group but not in the placebo group. At the same time, insomnia, somnolence, and agitation were reported in both groups, with a higher percentage in the citalopram group.*
Label Image (Lbl500905172)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
